



Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference

June 8, 2022

ALPHARETTA, Ga., June 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS[®]), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022, at 9:30 a.m. Eastern Time, in New York, NY.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: [Events and Presentations](#). An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS[®]). Clearside's SCS injection platform, utilizing the Company's proprietary SCS Microinjector[®], enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside's first product, [XIPERE[®]](#) (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.